Last 12 months
Inside the activity.
0 purchase rows · 204 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 17 |
| Dec 2025 | 0 | 26 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 8 |
| Jun 2026 | 0 | 32 |
| Jul 2026 | 0 | 64 |
| Aug 2026 | 0 | 27 |
| Sep 2026 | 0 | 20 |
| Oct 2026 | 0 | 5 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 06, 2021 Filed Jul 8, 2021 23:09 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
SaleAmerican Depositary Shares | 700 | $328.07 | $229,645.99 |
DisclosureSEC source: 0001651308-21-000150 · wf-form4_162578573814902.xml · nonDerivative · entry 14 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2020. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $327.79 to $328.28, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 23:09 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
SaleAmerican Depositary Shares | 2,290 | $327.22 | $749,336.55 |
DisclosureSEC source: 0001651308-21-000150 · wf-form4_162578573814902.xml · nonDerivative · entry 13 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2020. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $326.70 to $327.637, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 23:09 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
SaleAmerican Depositary Shares | 3,015 | $326.28 | $983,723.04 |
DisclosureSEC source: 0001651308-21-000150 · wf-form4_162578573814902.xml · nonDerivative · entry 12 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,190 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2020. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $325.69 to $326.68, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 23:09 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
SaleAmerican Depositary Shares | 885 | $325.01 | $287,634.29 |
DisclosureSEC source: 0001651308-21-000150 · wf-form4_162578573814902.xml · nonDerivative · entry 11 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,205 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2020. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $324.44 to $325.27, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 23:09 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
SaleAmerican Depositary Shares | 2,023 | $323.63 | $654,710.37 |
DisclosureSEC source: 0001651308-21-000150 · wf-form4_162578573814902.xml · nonDerivative · entry 10 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,090 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2020. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $323.2667 to $324.18, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 23:09 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
SaleAmerican Depositary Shares | 3,062 | $322.93 | $988,799.41 |
DisclosureSEC source: 0001651308-21-000150 · wf-form4_162578573814902.xml · nonDerivative · entry 9 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,113 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2020. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $322.2616 to $323.26, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 23:09 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
SaleAmerican Depositary Shares | 900 | $321.72 | $289,550.07 |
DisclosureSEC source: 0001651308-21-000150 · wf-form4_162578573814902.xml · nonDerivative · entry 8 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,175 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2020. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $321.20 to $322.1055, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 23:09 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
SaleOrdinary Shares | 44,300 | $25.42 | $1,126,048.41 |
DisclosureSEC source: 0001651308-21-000150 · wf-form4_162578573814902.xml · nonDerivative · entry 1 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,722,631 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2020. F2 · price: The price reported in Column 4 is a weighted average price per ordinary share. One ordinary share equals 1/13 American Depositary Share. These shares were sold in multiple transactions at prices ranging from $25.0153 to $25.9293, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of ordinary shares sold at each separate price. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:25 UTC |
Wu XiaobinPresident, COO & GM China
|
SaleAmerican Depositary Shares | 100 | $331.88 | $33,188.00 |
DisclosureSEC source: 0001651308-21-000149 · wf-form4_162578307197535.xml · nonDerivative · entry 11 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2020. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:25 UTC |
Wu XiaobinPresident, COO & GM China
|
SaleAmerican Depositary Shares | 100 | $329.60 | $32,959.53 |
DisclosureSEC source: 0001651308-21-000149 · wf-form4_162578307197535.xml · nonDerivative · entry 10 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2020. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $329.57 to $330.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:25 UTC |
Wu XiaobinPresident, COO & GM China
|
SaleAmerican Depositary Shares | 1,000 | $328.19 | $328,190.60 |
DisclosureSEC source: 0001651308-21-000149 · wf-form4_162578307197535.xml · nonDerivative · entry 9 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2020. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $327.81 to $328.76, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:25 UTC |
Wu XiaobinPresident, COO & GM China
|
SaleAmerican Depositary Shares | 2,610 | $327.26 | $854,156.17 |
DisclosureSEC source: 0001651308-21-000149 · wf-form4_162578307197535.xml · nonDerivative · entry 8 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $326.81 to $327.76, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:25 UTC |
Wu XiaobinPresident, COO & GM China
|
SaleAmerican Depositary Shares | 2,114 | $326.30 | $689,804.33 |
DisclosureSEC source: 0001651308-21-000149 · wf-form4_162578307197535.xml · nonDerivative · entry 7 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,810 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $325.81 to $326.78, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:25 UTC |
Wu XiaobinPresident, COO & GM China
|
SaleAmerican Depositary Shares | 1,600 | $323.76 | $518,018.40 |
DisclosureSEC source: 0001651308-21-000149 · wf-form4_162578307197535.xml · nonDerivative · entry 6 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,924 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $323.55 to $324.33, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:25 UTC |
Wu XiaobinPresident, COO & GM China
|
SaleAmerican Depositary Shares | 2,256 | $323.15 | $729,024.82 |
DisclosureSEC source: 0001651308-21-000149 · wf-form4_162578307197535.xml · nonDerivative · entry 5 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,524 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $322.54 to $323.51, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:25 UTC |
Wu XiaobinPresident, COO & GM China
|
SaleAmerican Depositary Shares | 400 | $321.46 | $128,584.96 |
DisclosureSEC source: 0001651308-21-000149 · wf-form4_162578307197535.xml · nonDerivative · entry 4 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,780 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $321.19 to $321.65, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| July 01, 2021 Filed Jul 1, 2021 16:58 UTC |
Wang Julia AijunChief Financial Officer
|
SaleAmerican Depositary Shares | 308 | $349.06 | $107,511.68 |
DisclosureSEC source: 0001651308-21-000147 · wf-form4_162517305797222.xml · nonDerivative · entry 2 Wang Julia Aijun · CIK 0001860279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 30, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $348.9264 to $349.35, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 01, 2021 Filed Jul 1, 2021 22:01 UTC |
Wang XiaodongDirector · Chair, Scientific Advisory Brd
|
SaleAmerican Depositary Shares | 300 | $350.59 | $105,176.01 |
DisclosureSEC source: 0001651308-21-000148 · wf-form4_162517681283090.xml · nonDerivative · entry 11 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2018 to fulfill a tax payment obligation in connection with the vesting of restricted share unit awards previously granted to the Reporting Person. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.48 to $350.79, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 01, 2021 Filed Jul 1, 2021 22:01 UTC |
Wang XiaodongDirector · Chair, Scientific Advisory Brd
|
SaleAmerican Depositary Shares | 1,211 | $349.89 | $423,713.64 |
DisclosureSEC source: 0001651308-21-000148 · wf-form4_162517681283090.xml · nonDerivative · entry 10 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2018 to fulfill a tax payment obligation in connection with the vesting of restricted share unit awards previously granted to the Reporting Person. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $349.23 to $350.16, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 01, 2021 Filed Jul 1, 2021 22:01 UTC |
Wang XiaodongDirector · Chair, Scientific Advisory Brd
|
SaleAmerican Depositary Shares | 1,500 | $348.64 | $522,961.50 |
DisclosureSEC source: 0001651308-21-000148 · wf-form4_162517681283090.xml · nonDerivative · entry 9 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,511 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2018 to fulfill a tax payment obligation in connection with the vesting of restricted share unit awards previously granted to the Reporting Person. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $348.15 to $349.12, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 01, 2021 Filed Jul 1, 2021 22:01 UTC |
Wang XiaodongDirector · Chair, Scientific Advisory Brd
|
SaleAmerican Depositary Shares | 1,100 | $347.32 | $382,046.50 |
DisclosureSEC source: 0001651308-21-000148 · wf-form4_162517681283090.xml · nonDerivative · entry 8 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,011 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2018 to fulfill a tax payment obligation in connection with the vesting of restricted share unit awards previously granted to the Reporting Person. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $346.79 to $347.69, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 01, 2021 Filed Jul 1, 2021 22:01 UTC |
Wang XiaodongDirector · Chair, Scientific Advisory Brd
|
SaleAmerican Depositary Shares | 437 | $345.88 | $151,150.70 |
DisclosureSEC source: 0001651308-21-000148 · wf-form4_162517681283090.xml · nonDerivative · entry 7 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,111 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2018 to fulfill a tax payment obligation in connection with the vesting of restricted share unit awards previously granted to the Reporting Person. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $345.37 to $346.15, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 01, 2021 Filed Jul 1, 2021 22:01 UTC |
Wang XiaodongDirector · Chair, Scientific Advisory Brd
|
SaleAmerican Depositary Shares | 300 | $342.68 | $102,804.00 |
DisclosureSEC source: 0001651308-21-000148 · wf-form4_162517681283090.xml · nonDerivative · entry 6 Wang Xiaodong · CIK 0001662982 · Director · Chair, Scientific Advisory Brd 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,548 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2018 to fulfill a tax payment obligation in connection with the vesting of restricted share unit awards previously granted to the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $342.63 to $342.73, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 20:49 UTC |
Huang JaneCMO, Hematology
|
Exercise / conversionShare Option (Right to Buy) · Derivative | 19,500 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001651308-21-000140 · wf-form4_162508617914387.xml · derivative · entry 10 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,575 Underlying: Ordinary Shares · 19,500 shares Expires 2026-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F10 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of September 2, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 20:49 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 200 | $356.98 | $71,395.00 |
DisclosureSEC source: 0001651308-21-000140 · wf-form4_162508617914387.xml · nonDerivative · entry 9 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.82 to $357.13, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 20:49 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 300 | $355.26 | $106,578.00 |
DisclosureSEC source: 0001651308-21-000140 · wf-form4_162508617914387.xml · nonDerivative · entry 8 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $355.03 to $355.38, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 20:49 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 200 | $352.95 | $70,589.00 |
DisclosureSEC source: 0001651308-21-000140 · wf-form4_162508617914387.xml · nonDerivative · entry 7 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $352.48 to $353.41, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 20:49 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 400 | $351.06 | $140,425.00 |
DisclosureSEC source: 0001651308-21-000140 · wf-form4_162508617914387.xml · nonDerivative · entry 6 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.74 to $351.30, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 20:49 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 100 | $349.22 | $34,922.00 |
DisclosureSEC source: 0001651308-21-000140 · wf-form4_162508617914387.xml · nonDerivative · entry 5 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 20:49 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 300 | $347.63 | $104,289.00 |
DisclosureSEC source: 0001651308-21-000140 · wf-form4_162508617914387.xml · nonDerivative · entry 4 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $347.45 to $347.72, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 20:49 UTC |
Huang JaneCMO, Hematology
|
Exercise / conversionAmerican Depositary Shares | 1,500 | $29.49 | $44,235.00 |
DisclosureSEC source: 0001651308-21-000140 · wf-form4_162508617914387.xml · nonDerivative · entry 3 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 20:48 UTC |
Wang LaiGlobal Head of R&D
|
SaleAmerican Depositary Shares | 455 | $362.48 | $164,929.95 |
DisclosureSEC source: 0001651308-21-000139 · wf-form4_162508606172808.xml · nonDerivative · entry 2 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 26, 2018, subject to continued service. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $362.331 to $362.82, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 20:49 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 425 | $365.00 | $155,125.00 |
DisclosureSEC source: 0001651308-21-000140 · wf-form4_162508617914387.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 26, 2018, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 20:45 UTC |
Liang HowardCFO & Chief Strategy Officer
|
SaleAmerican Depositary Shares | 446 | $365.00 | $162,790.00 |
DisclosureSEC source: 0001651308-21-000138 · wf-form4_162508592671674.xml · nonDerivative · entry 2 Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 26, 2018, subject to continued service. Unvested securities are subject to accelerated vesting upon a sale event. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 20:47 UTC |
Wang LaiGlobal Head of R&D
|
SaleAmerican Depositary Shares | 802 | $331.15 | $265,583.18 |
DisclosureSEC source: 0001651308-21-000127 · wf-form4_162430843229244.xml · nonDerivative · entry 2 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 17, 2020, subject to continued service. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $330.78 to $331.62, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 20:45 UTC |
Huang JaneCMO, Hematology
|
SaleAmerican Depositary Shares | 469 | $325.66 | $152,733.04 |
DisclosureSEC source: 0001651308-21-000126 · wf-form4_162430832547020.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 17, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 20:49 UTC |
Wu XiaobinPresident, COO & GM China
|
SaleAmerican Depositary Shares | 1,156 | $330.93 | $382,550.57 |
DisclosureSEC source: 0001651308-21-000128 · wf-form4_162430851498091.xml · nonDerivative · entry 4 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 17, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $330.9148 to $331.045, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 20:43 UTC |
Liang HowardCFO & Chief Strategy Officer
|
SaleAmerican Depositary Shares | 486 | $325.89 | $158,383.46 |
DisclosureSEC source: 0001651308-21-000125 · wf-form4_162430820122597.xml · nonDerivative · entry 2 Liang Howard · CIK 0001663427 · CFO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 17, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon a sale event. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:12 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
GrantShare Option (Right to Buy) · Derivative | 34,996 | $0.00 Strike: $26.53 | $0.00 |
DisclosureSEC source: 0001638599-21-000583 · doc4_7279.xml · derivative · entry 9 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 34,996 Underlying: Ordinary Shares · 34,996 shares Expires 2031-06-15 F12 · derivative.exercise_date: 17,498 Share Options each granted to Michael Goller and Ranjeev Krishana, full-time employees of the Adviser, in their capacity as directors of the Issuer under the Issuer's 2016 Share Option and Incentive Plan (the "2016 Plan"). The Share Options have a strike price of $26.53 and vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting of the Issuer, provided, however, that all vesting shall cease if Michael Goller or Ranjeev Krishana resigns from the Board or otherwise ceases to serve as a director, unless the Board determines otherwise. F1 · ownership.nature: American Depositary Shares ("ADS") of BeiGene, Ltd. (the "Issuer") each represent 13 Ordinary Shares ("Ordinary Shares") of the Issuer. F8 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. F9 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F11 · ownership.nature: Pursuant to the policies of the Adviser, Michael Goller and Ranjeev Krishana do not have any right to any of the Issuer's securities issued as part of their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the Ordinary Shares received upon vesting of RSUs and non-qualified share options convertible solely into Ordinary Shares of the Issuer ("Share Options") received as a result of their service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Ordinary Shares received upon vesting of RSUs, Share Options, and Ordinary Shares received upon the exercise of Share Options (i.e. no direct pecuniary interest). F12 · ownership.nature: 17,498 Share Options each granted to Michael Goller and Ranjeev Krishana, full-time employees of the Adviser, in their capacity as directors of the Issuer under the Issuer's 2016 Share Option and Incentive Plan (the "2016 Plan"). The Share Options have a strike price of $26.53 and vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting of the Issuer, provided, however, that all vesting shall cease if Michael Goller or Ranjeev Krishana resigns from the Board or otherwise ceases to serve as a director, unless the Board determines otherwise. F13 · ownership.nature: The Share Options expire on June 15, 2031. Michael Goller and Ranjeev Krishana serve on the Board of the Issuer as representatives of the Funds. Unvested Share Options are subject to accelerated vesting upon a change in control and certain termination events. F14 · ownership.nature: The Adviser, has voting and dispositive power over the Share Options, RSUs and any Ordinary Shares received as a result of the exercise of Share Options or vesting of RSUs. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:12 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
GrantOrdinary Shares | 15,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-21-000583 · doc4_7279.xml · nonDerivative · entry 8 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 34,189 F1 · ownership.nature: American Depositary Shares ("ADS") of BeiGene, Ltd. (the "Issuer") each represent 13 Ordinary Shares ("Ordinary Shares") of the Issuer. F7 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Baker Brothers Life Sciences, L.P, ("Life Sciences", and together with 667, the "Funds"), Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in Ordinary Shares or ADS, as applicable, reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. F8 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. F9 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F10 · ownership.nature: Includes beneficial ownership of 9,282 Ordinary Shares received from vested restricted share units convertible solely into Ordinary Shares of the Issuer ("RSUs") each previously granted to Michael Goller and Ranjeev Krishana, full-time employees of the Adviser, in their capacity as directors of the Issuer. Michael Goller and Ranjeev Krishana serve on the board of directors of the Issuer (the "Board") as representatives of the Funds. F11 · ownership.nature: Pursuant to the policies of the Adviser, Michael Goller and Ranjeev Krishana do not have any right to any of the Issuer's securities issued as part of their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the Ordinary Shares received upon vesting of RSUs and non-qualified share options convertible solely into Ordinary Shares of the Issuer ("Share Options") received as a result of their service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Ordinary Shares received upon vesting of RSUs, Share Options, and Ordinary Shares received upon the exercise of Share Options (i.e. no direct pecuniary interest). F14 · ownership.nature: The Adviser, has voting and dispositive power over the Share Options, RSUs and any Ordinary Shares received as a result of the exercise of Share Options or vesting of RSUs. F15 · ownership.nature: 7,800 RSUs granted to each of Michael Goller and Ranjeev Krishana on June 16, 2021, pursuant to the 2016 Plan. The RSUs vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting of the Issuer, provided, however, that all vesting shall cease if Michael Goller or Ranjeev Krishana resigns from the Board or otherwise ceases to serve as a director, unless the Board determines otherwise. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:12 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
GrantOrdinary Shares | 15,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-21-000583 · doc4_7279.xml · nonDerivative · entry 7 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 34,185 F1 · ownership.nature: American Depositary Shares ("ADS") of BeiGene, Ltd. (the "Issuer") each represent 13 Ordinary Shares ("Ordinary Shares") of the Issuer. F6 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Ordinary Shares or ADS, as applicable, reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. F8 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. F9 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F10 · ownership.nature: Includes beneficial ownership of 9,282 Ordinary Shares received from vested restricted share units convertible solely into Ordinary Shares of the Issuer ("RSUs") each previously granted to Michael Goller and Ranjeev Krishana, full-time employees of the Adviser, in their capacity as directors of the Issuer. Michael Goller and Ranjeev Krishana serve on the board of directors of the Issuer (the "Board") as representatives of the Funds. F11 · ownership.nature: Pursuant to the policies of the Adviser, Michael Goller and Ranjeev Krishana do not have any right to any of the Issuer's securities issued as part of their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the Ordinary Shares received upon vesting of RSUs and non-qualified share options convertible solely into Ordinary Shares of the Issuer ("Share Options") received as a result of their service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Ordinary Shares received upon vesting of RSUs, Share Options, and Ordinary Shares received upon the exercise of Share Options (i.e. no direct pecuniary interest). F14 · ownership.nature: The Adviser, has voting and dispositive power over the Share Options, RSUs and any Ordinary Shares received as a result of the exercise of Share Options or vesting of RSUs. F15 · ownership.nature: 7,800 RSUs granted to each of Michael Goller and Ranjeev Krishana on June 16, 2021, pursuant to the 2016 Plan. The RSUs vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting of the Issuer, provided, however, that all vesting shall cease if Michael Goller or Ranjeev Krishana resigns from the Board or otherwise ceases to serve as a director, unless the Board determines otherwise. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:57 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
GrantShare Option (Right to Buy) · Derivative | 906,906 | $0.00 Strike: $26.53 | $0.00 |
DisclosureSEC source: 0001651308-21-000131 · wf-form4_162430901944168.xml · derivative · entry 7 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 906,906 Underlying: Ordinary Shares · 906,906 shares Expires 2031-06-15 F7 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F7 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F8 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of June 16, 2021 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested shares are subject to accelerated vesting upon change of control or certain termination events. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:57 UTC |
OYLER JOHNDirector · Chief Executive Officer
|
GrantOrdinary Shares | 146,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-21-000131 · wf-form4_162430901944168.xml · nonDerivative · entry 1 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,936,906 F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 16, 2021, subject to continued service. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:47 UTC |
Wang LaiGlobal Head of R&D
|
GrantShare Option (Right to Buy) · Derivative | 332,527 | $0.00 Strike: $26.53 | $0.00 |
DisclosureSEC source: 0001651308-21-000127 · wf-form4_162430843229244.xml · derivative · entry 3 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,527 Underlying: Ordinary Shares · 332,527 shares Expires 2031-06-15 F5 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. F5 · shares: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. F6 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on June 16, 2022, and the remaining in 36 successive equal monthly installments, subject to continued service. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:47 UTC |
Wang LaiGlobal Head of R&D
|
GrantOrdinary Shares | 53,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-21-000127 · wf-form4_162430843229244.xml · nonDerivative · entry 1 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,654 F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 16, 2021, subject to continued service. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:45 UTC |
Huang JaneCMO, Hematology
|
GrantShare Option (Right to Buy) · Derivative | 157,196 | $0.00 Strike: $26.53 | $0.00 |
DisclosureSEC source: 0001651308-21-000126 · wf-form4_162430832547020.xml · derivative · entry 3 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,196 Underlying: Ordinary Shares · 157,196 shares Expires 2031-06-15 F4 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. F4 · shares: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. F5 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on June 16, 2022, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:45 UTC |
Huang JaneCMO, Hematology
|
GrantOrdinary Shares | 25,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-21-000126 · wf-form4_162430832547020.xml · nonDerivative · entry 1 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,186 F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 16, 2021, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:37 UTC |
Malley ThomasDirector
|
GrantShare Option (Right to Buy) · Derivative | 17,498 | $0.00 Strike: $26.53 | $0.00 |
DisclosureSEC source: 0001651308-21-000121 · wf-form4_162430781053430.xml · derivative · entry 3 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,498 Underlying: Ordinary Shares · 17,498 shares Expires 2031-06-15 F3 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F3 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F4 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:37 UTC |
Malley ThomasDirector
|
GrantOrdinary Shares | 7,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-21-000121 · wf-form4_162430781053430.xml · nonDerivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,082 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 16:42 UTC |
Chen Timothy Yung-ChengDirector
|
GrantShare Option (Right to Buy) · Derivative | 17,498 | $0.00 Strike: $26.53 | $0.00 |
DisclosureSEC source: 0001651308-21-000124 · wf-form4_162430808259171.xml · derivative · entry 2 Chen Timothy Yung-Cheng · CIK 0001374068 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,498 Underlying: Ordinary Shares · 17,498 shares Expires 2031-06-15 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.